PR Newswire Europe - Acomplia(R) (Rimonabant) Recommended for Approval in the European Union.
Most Popular
13 Job Interview Mistakes To Avoid
10 Jobs That Pay $30 An Hour
Public Speaking: 7 Secrets Of Great Public Speakers
5 Regular Mistakes In Public Speaking
Employee Incentive Program - Getting The Best Value For Money
> PARIS, France, April 28 /PRNewswire/ — Sanofi-aventis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant marketing authorisation in the European Union for ACOMPLIA(R) (rimonabant 20mg) for the following indication: ” As an adjunct to diet and exercise for the treatment of obese patients (BMI greater than or equal to 30kg/m2), or overweight patients (BMI > 27 kg/m2) with associated risk factors, such as type 2 diabetes or dyslipidemia (see section …
Read the rest of this article with a Free Trial at HighBeam Research.
